Merck KGaA and Kadimastem collaborate on drug screening; TVM focuses on biopharma, med tech;

@FierceBiotech: Roche heralds its return to the antibiotics field with $560M Polyphor deal. More | Follow @FierceBiotech

@JohnCFierce: ICYMI over the weekend: Merck's next-gen HPV vaccine looks good in PhIII, but sales may disappoint. Story | Follow @JohnCFierce

@DamianFierce: Oral testosterone developer Lipocine swings for $11.5M in S-1. More | Follow @DamianFierce

@EmilyMFierce: ICYMI: Key HIV protein structure revealed, paving way for new HIV/AIDS vaccine efforts. Story | Follow @EmilyMFierce

> Merck Serono and Kadimastem have set out to collaborate on a stem cell-based drug screening initiative. Report

> TVM Capital says it will give up its investment activities in the IT field in favor of biopharmaceuticals and med tech. The venture group has offices in Munich and Montreal with an equity team in Dubai that invests in healthcare delivery. Release

> Xencor laid out its IPO plans today, saying it will set out to sell 5 million shares at a range of $14 to $16 a share. At the midway point, that would raise $75 million. Story

Medical Device News

@FierceMedDev: ICYMI: OrbiMed kicks off $735M VC fund with device and Dx companies in mind. Story | Follow @FierceMedDev

@MarkHFierce: The U.K. is banning the use of all-metal hips at NHS Hospitals. More | Follow @MarkHFierce

@MichaelGFierce: ICYMI: IBM uses hydrogel to prolong delivery of Roche's Herceptin. More from FierceDrugDelivery | Follow @MichaelGFierce

> Insulin pump maker Tandem craves $123M in up-sized IPO. News

> Terumo buys into Turkey's blood collection market. More

> Illumina, Natera, Ariosa ink deals with CA's prenatal Dx program. Item

Pharma News

@FiercePharma: HHS gives pharma the all-clear on co-pay assistance for Obamacare patients. Article | Follow @FiercePharma

@EricPFierce: Merck layoffs roll through to West Point, Pa plant with 500 jobs slated to go over X-mas holidays. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: FDA helps generic drugmakers get copies of Glaxo's Advair to market. More | Follow @CarlyHFierce

> Reuters: GlaxoSmithKline likely to escape China charges, but execs probably won't. Story

> Ex-Lilly contract sales rep sues, claiming unpaid bonuses. News

CRO News

> Venn grabs German CRO, expands Euro footprint. Item

> Charles River bucks trend with spike in preclinical sales. Story

> Covance ups expectations thanks to booming lab biz. News

> Quintiles hikes income outlook as contracts pour in. More

> InVentiv grabs Catalina Health with eye on patient adherence. Report

> Parexel's stock plunges despite spikes in revenue, profit. Article

Biotech IT News

> NuMedii taps Thomson Reuters for data to power digital discovery model. More

> GoBalto rolls out version 2.0 of Tracker software. Item

> Rhenovia creates simulation of epilepsy biology. Story

> Rare disease dictionary gives bioinformatics databases a shared language. Article

> FDA working on drug shortages smartphone app. News

> Illumina to buy bioinformatics business NextBio. Report

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.